Carolyn Anderson did her PhD training at Florida State University, studying the behavior of actinides in the environment to receive her PhD in Inorganic Chemistry. Afterwards, she moved to the Washington University in St. Louis as a postdoctoral fellow under Professor Michael J Welch’s mentorship. She designed and tested receptor-targeted agents labeled with radiometals for imaging and therapy of cancer. Her research laid a foundation for the growth of radiometal-based agents for imaging and therapy (“theranostics”). After 20 years at Washington University where she was a Professor of Radiology, she moved to the University of Pittsburgh, where the focus was on imaging immune cells in diseases that included cancer, tuberculosis, and sickle cell disease. Prof. Anderson’s unique expertise in radiochemistry and medical applications in cancer and other diseases complement the ongoing research at the University of Missouri (MU), where she moved to in 2020. Her goal for the Molecular Imaging and Theranostics Center (MITC), a facility that she directs, is to establish it as a hub for collaborators throughout the MU campus and beyond for the discovery of novel radiolabeled agents that can see and/or treat cancer. Prof. Anderson has received numerous honors, including the Michael J. Welch Award from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in 2012, a Distinguished Investigator Award from the Academy of Radiology Research in 2014, the Paul C. Aebersold award (SNMMI) for outstanding achievement for basic science research applied to nuclear medicine in 2020, and the Glenn T. Seaborg award in Nuclear Chemistry from the American Chemical Society in 2022.